Valuation: Scancell Holdings plc

Market Cap 116M 158M 136M 128M 219M 15.08B 222M 1.5B 586M 7.55B 592M 579M 25.09B P/E 2026 *
-6.42x
P/E 2027 * -12.2x
Enterprise Value 127M 172M 148M 139M 238M 16.43B 242M 1.63B 639M 8.23B 645M 631M 27.33B EV / Sales 2026 *
101x
EV / Sales 2027 * 55.1x
Free-Float
96.87%
Yield 2026 *
-
Yield 2027 * -
1 day+0.42%
1 week+1.59%
Current month-1.54%
1 month-27.27%
3 months-57.80%
6 months-31.43%
Current year-3.03%
1 week 9.4
Extreme 9.4
9.7
1 month 9.3
Extreme 9.3
14
Current year 9.3
Extreme 9.3
29.5
1 year 7.86
Extreme 7.8555
29.5
3 years 7.26
Extreme 7.26
29.5
5 years 7.26
Extreme 7.26
29.5
10 years 0.11
Extreme 0.1118
29.5
Manager TitleAgeSince
Chief Executive Officer 69 28/07/2021
Chief Executive Officer 64 18/11/2024
Director of Finance/CFO 50 24/04/2026
Director TitleAgeSince
Director/Board Member 69 17/11/2010
Director/Board Member 74 23/10/2019
Director/Board Member 64 24/09/2020
Date Insider Type Main position Quantity % Market Cap.
16/09/25
Vulpes Investment Management Pte Ltd.
BuyCompany 3,150,000 0.3038%
08/08/25
Vulpes Investment Management Pte Ltd.
BuyCompany 102,236 0.0099%
04/08/25
Vulpes Investment Management Pte Ltd.
BuyCompany 4,400,000 0.4244%
Change 5-day change 1-year change 3-year change Capi.($)
+0.42%+1.59%-8.57%-14.67% 158M
-1.78%-1.68%+1.48%+15.31% 48.42B
+0.85%-0.70%+460.88%+563.55% 43.66B
-2.40%-0.23%+8.13%+71.41% 39.51B
-2.01%-0.85%+23.85%+8.73% 38.95B
-0.50%+0.85%+20.60%+49.65% 32.61B
+0.38%-3.23% - - 16.32B
-0.59%-2.06%+26.35%+118.09% 16.15B
+0.49%+0.92%+4.11%+23.67% 14.16B
-0.43%+4.70%+78.74%+33.31% 13.37B
Average -0.56%+0.60%+68.40%+96.56% 26.33B
Weighted average by Cap. -0.91%+0.59%+95.76%+132.85%

Financials

2026 *2027 *
Net sales 1.25M 1.69M 1.46M 1.37M 2.35M 162M 2.39M 16.1M 6.3M 81.09M 6.36M 6.22M 269M 2.4M 3.25M 2.81M 2.64M 4.51M 311M 4.59M 30.92M 12.09M 156M 12.21M 11.94M 517M
Net income -19.23M -26.06M -22.51M -21.15M -36.16M -2.49B -36.76M -248M -96.89M -1.25B -97.84M -95.71M -4.15B -8.24M -11.16M -9.64M -9.06M -15.49M -1.07B -15.74M -106M -41.49M -534M -41.9M -40.99M -1.78B
Net Debt 10.42M 14.11M 12.19M 11.45M 19.58M 1.35B 19.91M 134M 52.47M 676M 52.98M 51.83M 2.25B 15.87M 21.51M 18.57M 17.45M 29.84M 2.06B 30.34M 205M 79.96M 1.03B 80.75M 78.99M 3.42B
Logo Scancell Holdings plc
Scancell Holdings plc is a clinical-stage biopharmaceutical company. The Company is engaged in studying the human adaptive immune system, to generate medicines to treat unmet needs in cancer. The Company is building a pipeline of products by utilizing its four technology platforms: Moditope and ImmunoBody for vaccines and GlyMab and AvidiMab for antibodies. Its product pipeline includes Modi-1, Modi-2, SCIB1 & iSCIB1+, SCIB2, SC129, SC134, SC2811, SC27, and others. Modi-1 is the first therapeutic vaccine candidate from the Company’s Moditope platform, which targets citrullinated peptides from two different proteins which have been combined to reduce the possibility of tumor escape and have each been conjugated to a toll-like receptor (TLR) 1/2 agonist, which acts as an adjuvant. Modi-2, which targets homocitrullinated cancer antigens, is the second therapeutic vaccine candidate from the Company’s Moditope platform and has the potential to address different cancer indications to Modi-1.
Employees
60
Date Price Change Volume
14/08/26 GBX 9.600 +0.42% 886,705
13/08/26 GBX 9.560 -0.42% 1,381,677
12/08/26 GBX 9.600 0.00% 992,478
11/08/26 GBX 9.600 +1.05% 3,969,591
10/08/26 GBX 9.500 +0.53% 4,518,969
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.0960GBP
Average target price
0.2550GBP
Spread / Average Target
+165.62%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SCLP Stock